Status:
UNKNOWN
Ganciclovir Resistant Cytomegalovirus Infection in SOT Recipients.
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Cytomegalovirus Infections
Eligibility:
All Genders
18+ years
Brief Summary
ReCySOT study is a multicenter, retrospective, observational case-control study on risk factors for developing a ganciclovir-resistant (GCV-R) cytomegalovirus infection in patients receiving solid org...
Detailed Description
Cytomegalovirus (CMV) is an important cause of morbidity and mortality in solid organ transplant (SOT) patients. Ganciclovir is the first line therapy for treatment and prevention of CMV infection in ...
Eligibility Criteria
Inclusion
- Diagnosis of CMV infection in adult (age ≥ 18 years) patients underwent SOT
- Ability to understand the purpose of the study and provide signed and dated informed consent
Exclusion
- Lack of clinical and/or laboratory data to establish the type of CMV event
- Lack of the serological mismatch at transplantation
- Lack of the type of SOT
- Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05234723
Start Date
February 1 2022
End Date
June 30 2022
Last Update
February 10 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.